These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 9870249)

  • 21. Why commonplace encounters turn to fatal attraction.
    Sadelain M; Kieff E
    Nat Genet; 1998 Oct; 20(2):103-4. PubMed ID: 9771693
    [No Abstract]   [Full Text] [Related]  

  • 22. Therapy for transplant-related lymphoproliferative diseases.
    Benkerrou M; Durandy A; Fischer A
    Hematol Oncol Clin North Am; 1993 Apr; 7(2):467-75. PubMed ID: 8385662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Post-transplantation lymphomas and Epstein-Barr virus].
    Caillard S; Heibel F; Benaicha M; Moulin B
    Nephrologie; 1998; 19(8):481-8. PubMed ID: 9894641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recurrent Epstein-Barr virus-associated lesions in organ transplant recipients.
    Wu TT; Swerdlow SH; Locker J; Bahler D; Randhawa P; Yunis EJ; Dickman PS; Nalesnik MA
    Hum Pathol; 1996 Feb; 27(2):157-64. PubMed ID: 8617457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients.
    Nalesnik MA; Rao AS; Furukawa H; Pham S; Zeevi A; Fung JJ; Klein G; Gritsch HA; Elder E; Whiteside TL; Starzl TE
    Transplantation; 1997 May; 63(9):1200-5. PubMed ID: 9158009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders.
    Delecluse HJ; Kremmer E; Rouault JP; Cour C; Bornkamm G; Berger F
    Am J Pathol; 1995 May; 146(5):1113-20. PubMed ID: 7747805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reexamining post-transplant lymphoproliferative disorders: Newly recognized and enigmatic types.
    Aguilera N; Gru AA
    Semin Diagn Pathol; 2018 Jul; 35(4):236-246. PubMed ID: 29615296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of donor versus recipient type Epstein-Barr virus in post-transplant lymphoproliferative disorders.
    Haque T; Crawford DH
    Springer Semin Immunopathol; 1998; 20(3-4):375-87. PubMed ID: 9870252
    [No Abstract]   [Full Text] [Related]  

  • 29. Analysis of the T-cell micro-environment in Epstein-Barr virus-related post-transplantation B lymphoproliferative disease.
    Perera SM; Thomas JA; Burke M; Crawford DH
    J Pathol; 1998 Feb; 184(2):177-84. PubMed ID: 9602709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients.
    Green M; Michaels MG; Webber SA; Rowe D; Reyes J
    Pediatr Transplant; 1999 Nov; 3(4):271-81. PubMed ID: 10562971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epstein-Barr virus-related posttransplantation lymphoproliferative disorder involving pancreas allografts: histological differential diagnosis from acute allograft rejection.
    Drachenberg CB; Abruzzo LV; Klassen DK; Bartlett ST; Johnson LB; Kuo PC; Kumar D; Papadimitriou JC
    Hum Pathol; 1998 Jun; 29(6):569-77. PubMed ID: 9635676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transplantation-related lymphoproliferative disorder: a model for human immunodeficiency virus-related lymphomas.
    Swinnen LJ
    Semin Oncol; 2000 Aug; 27(4):402-8. PubMed ID: 10950366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease.
    Montone KT; Hodinka RL; Salhany KE; Lavi E; Rostami A; Tomaszewski JE
    Mod Pathol; 1996 Jun; 9(6):621-30. PubMed ID: 8782198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders.
    Rowe M; Niedobitek G; Young LS
    Springer Semin Immunopathol; 1998; 20(3-4):389-403. PubMed ID: 9870253
    [No Abstract]   [Full Text] [Related]  

  • 35. The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.
    Martinez OM; Krams SM
    Transplantation; 2017 Sep; 101(9):2009-2016. PubMed ID: 28376031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients.
    Wistinghausen B; Gross TG; Bollard C
    Pediatr Hematol Oncol; 2013 Sep; 30(6):520-31. PubMed ID: 23802715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-10 production by a B-cell line derived from human post-transplant lymphoproliferative disease.
    Randhawa P; Nalesnik M; Demetris J; Zeevi A
    Hematol Oncol; 1995; 13(1):13-8. PubMed ID: 7750924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Central nervous system T-cell lymphoproliferative disorder in a patient with chronic active Epstein-Barr virus infection.
    Ohga S; Takada H; Honda K; Inamura T; Gondo K; Ohshima K; Yamamoto M; Hara T
    J Pediatr Hematol Oncol; 1999; 21(1):42-6. PubMed ID: 10029811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T gamma/delta hepatosplenic lymphoma in a heart transplant patient after an Epstein-Barr virus positive lymphoproliferative disorder: a case report.
    Kraus MD; Crawford DF; Kaleem Z; Shenoy S; MacArthur CA; Longtine JA
    Cancer; 1998 Mar; 82(5):983-92. PubMed ID: 9486591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
    Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
    Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.